Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/62667, first published .
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial

Journals

  1. Karakasis P, Patoulias D, Fragakis N, Mantzoros C. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism 2025;164:156113 View
  2. Espinoza S, Broder J, Wolfe R, Ernst M, Shah R, Orchard S, Woods R, Ryan J, Murray A. Frailty incidence by diabetes treatment regimens in older adults with diabetes mellitus in the ASPirin in Reducing Events in the Elderly Study. GeroScience 2025;47(3):5169 View
  3. Miousse I. GLP-1 receptor agonists in the context of cancer: the road ahead. American Journal of Physiology-Cell Physiology 2025;328(6):C1822 View
  4. Koceva A, Janež A, Jensterle M. Impact of Incretin-Based Therapy on Skeletal Muscle Health. Medicina 2025;61(9):1691 View
  5. Dinkla L, Beavers K, Robbins R, Akpalu D, Wherry S, Miller G, Beavers D, Espinoza S, Trejo J, Stepanenko A, Cortes T. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis. Frontiers in Aging 2025;6 View